CytoDyn(DE:296)
€0.19+0.02 (+11.76%)
DE:296
CytoDyn financials statements
€0.19
At close:+0.02 (+11.76%)
CytoDyn (296) Ratios
0 Followers
CytoDyn Ratios
DE:296's free cash flow for Q1 2027 was $-7.73M. For the 2027 fiscal year, DE:296's free cash flow was increased by $0.00 and operating cash flow was $-7.73M. See a summary of the company’s cash flow.
| Ratios | May 26 | May 25 | May 24 | May 23 | May 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.26 | 0.25 | 0.13 | 0.09 | 0.23 |
| Quick Ratio | 0.26 | 0.25 | 0.13 | 0.09 | 0.09 |
| Cash Ratio | 0.22 | 0.17 | 0.04 | 0.02 | 0.03 |
| Solvency Ratio | -0.35 | 0.03 | -0.39 | -0.66 | -1.70 |
| Operating Cash Flow Ratio | -0.32 | -0.12 | -0.13 | -0.21 | -0.63 |
| Short-Term Operating Cash Flow Coverage | -1.44 | -0.32 | -0.37 | -0.73 | -2.14 |
| Net Current Asset Value | $ -109.81M | $ -96.21M | $ -117.08M | $ -109.99M | $ -95.14M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.74 | 1.51 | 2.70 | 3.14 | 1.26 |
| Debt-to-Equity Ratio | -0.35 | -0.28 | -0.26 | -0.32 | -0.39 |
| Debt-to-Capital Ratio | -0.54 | -0.40 | -0.35 | -0.48 | -0.64 |
| Long-Term Debt-to-Capital Ratio | -0.32 | 0.00 | 0.00 | -0.01 | 0.00 |
| Financial Leverage Ratio | -0.13 | -0.19 | -0.10 | -0.10 | -0.31 |
| Debt Service Coverage Ratio | -1.50 | 0.27 | -0.47 | -0.68 | -2.20 |
| Interest Coverage Ratio | -8.69 | 2.33 | -2.08 | -1.61 | -2.77 |
| Debt to Market Cap | 0.10 | 0.07 | 0.19 | 0.16 | 0.16 |
| Interest Debt Per Share | 0.03 | 0.03 | 0.04 | 0.07 | 0.13 |
| Net Debt to EBITDA | -1.22 | 1.79 | -1.50 | -0.81 | -0.17 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.30% | 0.00% | 0.00% | 80.08% |
| EBIT Margin | 0.00% | -145.39% | 0.00% | 0.00% | -72680.08% |
| EBITDA Margin | 0.00% | -145.69% | 0.00% | 0.00% | -73298.12% |
| Operating Profit Margin | 0.00% | -191.41% | 0.00% | 0.00% | -54663.16% |
| Pretax Profit Margin | 0.00% | -63.30% | 0.00% | 0.00% | -79255.64% |
| Net Profit Margin | 0.00% | -63.30% | 0.00% | 0.00% | -79255.64% |
| Continuous Operations Profit Margin | 0.00% | -63.30% | 0.00% | 0.00% | -79255.64% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 195.77% | 33.07% | 276.01% | 196.73% | 144.99% |
| Return on Assets (ROA) | -305.58% | 20.75% | -447.57% | -706.91% | -722.36% |
| Return on Equity (ROE) | 38.92% | -3.90% | 42.69% | 72.90% | 223.33% |
| Return on Capital Employed (ROCE) | 54.86% | -21.58% | 24.72% | 37.40% | 154.72% |
| Return on Invested Capital (ROIC) | 78.65% | -45.06% | 41.89% | 54.87% | 252.43% |
| Return on Tangible Assets | -305.58% | 20.75% | -447.57% | -706.91% | -725.64% |
| Earnings Yield | -11.13% | 0.92% | -32.25% | -36.46% | -91.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | -2.96 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | -45.51 | 0.00 | 0.00 | 0.44 |
| Asset Turnover | 0.00 | -0.33 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.09 | 0.00 | 0.00 | -0.00 |
| Cash Conversion Cycle | -282445.59 | -298044.51 | -372060.86 | -130826.43 | -344649.53 |
| Days of Sales Outstanding | 0.00 | -123.39 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 123473.30 |
| Days of Payables Outstanding | 282445.59 | 297921.11 | 372060.86 | 130826.43 | 468122.83 |
| Operating Cycle | 0.00 | -123.39 | 0.00 | 0.00 | 123473.30 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.03 | -0.11 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.03 | -0.11 |
| Dividend Paid and CapEx Coverage Ratio | -11.65 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.45 | -0.32 | -0.37 | -0.71 | -2.11 |
| Operating Cash Flow to Sales Ratio | 0.00 | 1.48 | 0.00 | 0.00 | -292.19 |
| Free Cash Flow Yield | -4.50% | -2.14% | -7.11% | -11.47% | -33.77% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.68 | 178.37 | -3.10 | -2.74 | -1.09 |
| Price-to-Sales (P/S) Ratio | 0.00 | -69.07 | 0.00 | 0.00 | 865.21 |
| Price-to-Book (P/B) Ratio | -3.50 | -4.25 | -1.32 | -2.00 | -2.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -22.24 | -46.62 | -14.07 | -8.72 | -2.96 |
| Price-to-Operating Cash Flow Ratio | -22.24 | -46.62 | -14.07 | -8.72 | -2.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -1.72 | 0.07 | 0.04 | -0.03 |
| Enterprise Value Multiple | -18.82 | 49.20 | -10.07 | -6.23 | -1.35 |
| Enterprise Value | 410.25M | 424.07M | 181.51M | 251.79M | 262.71M |
| EV to EBITDA | -18.82 | 49.20 | -10.07 | -6.23 | -1.35 |
| EV to Sales | 0.00 | -71.68 | 0.00 | 0.00 | 987.64 |
| EV to Free Cash Flow | -23.78 | -48.38 | -16.53 | -10.03 | -3.38 |
| EV to Operating Cash Flow | -23.78 | -48.38 | -16.53 | -10.03 | -3.38 |
| Tangible Book Value Per Share | -0.09 | -0.08 | -0.12 | -0.13 | -0.14 |
| Shareholders’ Equity Per Share | -0.09 | -0.08 | -0.12 | -0.13 | -0.14 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.03 | 0.00 | -0.05 | -0.10 | -0.31 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.96 | 0.44 | 2.76 | 1.97 | 1.09 |
| Research & Development to Revenue | 0.00 | -2.86 | 0.00 | 0.00 | 101.67 |
| SG&A to Revenue | 0.00 | -1.23 | 0.00 | 0.00 | 166.55 |
| Stock-Based Compensation to Revenue | 0.00 | -0.27 | 0.00 | 0.00 | 23.55 |
| Income Quality | 0.40 | -2.34 | 0.22 | 0.31 | 0.37 |
Currency in USD
